Effectiveness and retention of certolizumab pegol and JAK inhibitors in rheumatoid arthritis: a multicenter retrospective study stratified by rheumatoid factor status. (PubMed, Front Med (Lausanne)) - Sep 25, 2026 - "This multicentre retrospective cohort included RA patients initiating CZP or JAKi (baricitinib, filgotinib, tofacitinib, upadacitinib) between 2010 and 2024. A numerical difference in treatment retention favouring CZP was also observed. These findings highlight the potential importance of considering RF levels when selecting treatment and warrant further investigation in prospective studies."
Journal • Retrospective data • Immunology • Inflammatory Arthritis • Rheumatoid Arthritis • Rheumatology
|
|
Alejandro Escudero-Contreras; Ana Martínez-Feito; Ana Valeria Acosta-Alfaro; Andrés Zúñiga-Vera; Antoni Juan-Mas; César Díaz-Torné; Chamaida Plasencia-Rodríguez; Clementina López-Medina; Cynthia Rojas; David Velasco-Sánchez; Delia Taverner-Torrent; Elena Moreno-Caño; Ester Costa-Moya; Fernando Ortiz-Márquez; Francisco José Cepas-Guitérrez; Isabel Añón-Oñate; Javier Godoy-Navarrete; Jerusalem Calvo-Gutiérrez; Laura Jiménez-Rodríguez; Lourdes Ladehesa-Pineda; Lourdes Martin-de la Sierra Lopez; Luis Sainz-Comas; María Martín-López; Marina Soledad Moreno-García; Mitndbaim Parra-Moreno; Montserrat Robustillo-Villarino; Natalia Mena-Vázquez; Paula Estrada; Rafaela Ortega-Castro; Raquel Zas; Regina Faré-García; Santiago Muñoz-Fernández; Virginia Ruiz-Esquide
|